A Novel Therapeutic Peptide as a Partial Agonist of RANKL in Ischemic Stroke

@inproceedings{Kurinami2016ANT,
  title={A Novel Therapeutic Peptide as a Partial Agonist of RANKL in Ischemic Stroke},
  author={Hitomi Kurinami and Munehisa Shimamura and Hironori Nakagami and Hideo Shimizu and Hiroshi Koriyama and Tomohiro Kawano and Kouji Wakayama and Hideki Mochizuki and Hiromi Rakugi and Ryuichi Morishita},
  booktitle={Scientific reports},
  year={2016}
}
The enhanced receptor activator of nuclear factor-κB (NFκB) ligand (RANKL) and its receptor (RANK) signal have been reported to attenuate ischemic brain injury through inhibition of Toll-like receptor (TLR) 4-mediated inflammation. However, augmentation of the RANKL/RANK signal also accelerates osteoporosis, which is a potential problem in clinical use of RANKL. Therefore, we developed novel peptides, microglial healing peptides (MHPs), which were based on the DE and/or EF loop of RANKL. Among… CONTINUE READING
4
Twitter Mentions